Participants were randomly assigned to receive once-weekly subcutaneous injections of tirzepatide (10 mg or 15 mg) or semaglutide (1.7 mg or 2.4 mg) for 72 weeks. Dosing began at 2.5 mg for ...

They analyzed the data of two patients who used GLP-1 RAs at less frequent dosing schedules than recommended; patient 1 with obesity and prediabetes self-administered 7.5 mg tirzepatide every 10 ...

2 It is available in six different dose strengths (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg), 3 providing healthcare providers with the ability to personalize treatment plans to better meet ...

INDIANAPOLIS, May 11, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced detailed results from SURMOUNT-5 ... mg or 2.4 mg). With tirzepatide, 89.3% received at least one dose ...

Participants achieved an average weight loss of 20.2% with Zepbound vs. 13.7% with Wegovy ...

"The SURMOUNT-5 head-to-head results ... a 1:1 ratio to receive maximum tolerated dose of Zepbound (10 mg or 15 mg) or Wegovy (1.7 mg or 2.4 mg). With tirzepatide, 89.3% received at least one ...

Participants achieved an average weight loss of 20.2% with Zepbound vs. 13.7% with Wegovy In key secondary endpoints, Zepbound was superior to Wegovy across all weight reduction targets and waist ...

Its twin offerings, Mounjaro and Zepbound—both based on tirzepatide—have demonstrated ... and is sold in 2.5 mg and 5 mg doses. Its dual-action mechanism—targeting both GLP-1 and GIP ...

3 The open-label, controlled SURMOUNT-5 trial enrolled adults with obesity but without type 2 diabetes. A total of 751 patients were randomly assigned in a 1:1 ratio to receive the maximum tolerated ...